This option is part of Emergent’s existing 10-year contract with BARDA for advanced development and procurement of Ebanga™, with a maximum value of $704 millionProgram progress and performance triggers $16.7 million contract option GAITHERSBURG, Md., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response within the U.S. Department of He ...

GAITHERSBURG, Md., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE: EBS), a leading public health company that delivers protective and life-saving solutions to communities across the world​, today announced that Joe C. Papa, president and chief executive officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 1:30 PM PST. The audio link for Emergent's session may be accessed here and will be live for up to 30 days. The company’s slides will ...

GAITHERSBURG, Md., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced the exercise of contract option and modification valued at approximately $20 million to supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of Defense (DoD). The first delivery, which was valued at approximately $7 million began in December 2024, and remaining deliveries are expected in 2025. “We’re pleased to continue our work with the U.S. Department of Defense to supply BioThrax® to ...

Company Overview - Emergent BioSolutions (EBS) stock gained nearly 12% on the day following an analyst's initiation of coverage, contrasting with the S&P 500's 1% decline [2] - H C Wainwright's Raghuram Selvaraju initiated coverage with a buy recommendation and a price target of $15 per share, which is 62% higher than the stock's current level [3] - The company is well positioned to be a frontline player in potential future healthcare emergencies due to its diversified offerings [4][6] Business Segments - The company's vaccines business includes jabs for monkeypox and smallpox, with monkeypox recently highlighted as a potential global healthcare threat [1] - Emergent's Narcan opioid reversal spray is expected to continue experiencing heavy demand due to the ongoing opioid epidemic in the U S [5] Analyst Perspective - Raghuram Selvaraju views Emergent as well diversified across several medical segments with strong growth potential [5] - The analyst's positive outlook on the company's diversification makes the stock a worthy consideration for investment [6]

Shares of Emergent BioSolutions (EBS) have more than doubled in market cap so far this year, outperforming the industry’s 13% decline, as seen in the chart below. This surge in stock price started earlier this year after management announced several strategic changes to enhance profitability and stabilize its financial position. During the same period, the stock has also outperformed the broader Medical sector and the S&P 500. It is currently trading above its 200-day moving average.EBS Stock Outperforms In ...

GAITHERSBURG, Md., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that the Biomedical Advanced Research and Development Authority (BARDA) within the Administration for Strategic Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services has awarded a $50 million option to Emergent's existing contract (HHSO100201600030C) for the acquisition of CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted). Deliveries are expected to begin this calendar yea ...

Emergent BioSolutions (EBS -5.59%) saw its shares tumble on Tuesday, due to news of a share sell-off. The vaccine maker divulged in a regulatory filing that several institutional share and warrant holders are selling such securities. Investors reacted by trading Emergent's stock down by almost 6%, on a day when the S&P 500 (^GSPC 0.05%) more or less flatlined.Unloading shares and exercising warrantsThe selling parties are mainly entities affiliated with OHA Agency, a business that provided a $250 million te ...

If you like what you have just read and want to receive at least 4 exclusive stock tips every week focused on Pharma, Biotech and Healthcare, then join me at my marketplace channel, Haggerston BioHealth . Invest alongside the model portfolio or simply access the investment bank-grade financial models and research. I hope to see you there.Emergent BioSolutions (NYSE: EBS ), the Gaithersburg, Maryland headquartered biotech reported its Q3 earnings on Wednesday 6th November, after the bell, leading to a 20% su ...

Core Viewpoint - Emergent BioSolutions Inc. reported mixed third-quarter earnings, with a notable increase in stock price driven by new mpox trials in Africa and a significant turnaround in adjusted EPS [1][5]. Financial Performance - Third-quarter sales reached $293.8 million, a 9% increase year over year, but fell short of the consensus estimate of $297.5 million [1]. - Adjusted EPS was $1.37, a recovery from a loss of $1.09 a year ago, exceeding the consensus of $0.14 [1]. Revenue Breakdown - Revenues from Narcan Nasal Spray decreased by 33% to $95.3 million due to the transition to over-the-counter sales and lower Canadian retail sales, although OTC Narcan sales increased [2]. - Anthrax MCM revenues fell by 65% to $11.4 million, while Smallpox MCM sales surged over fivefold to $132.7 million [2]. Guidance Updates - The company revised its 2024 revenue guidance to $1.065 billion – $1.125 billion, slightly below the previous range and consensus of $1.123 billion [3]. - Commercial product sales guidance was adjusted to $420 million – $430 million, down from $450 million – $480 million [3]. - MCM product sales outlook was updated to $510 million – $550 million, compared to the earlier expectation of $455 million – $490 million [3]. Services Segment and Loss Projections - Services segment sales are now expected to be $105 million – $110 million, lower than the previous range of $120 million – $130 million [4]. - The company anticipates a 2024 net loss of $203 million – $183 million, an improvement from the earlier loss range of $314 million – $274 million [4]. - Adjusted EBITDA is forecasted to be $180 million – $200 million, up from the previous forecast of $140 million – $180 million [4]. New Trials and Initiatives - Emergent BioSolutions announced a new trial for brincidofovir (Tembexa) to treat mpox, sponsored by PANTHER and led by the Africa Centres for Disease Control and Prevention, set to begin in the Democratic Republic of Congo [5]. Stock Performance - EBS stock increased by 28.3%, reaching $11.80 during the latest trading session [6].

Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today:Moody's Corporation (MCO) : This integrated risk assessment firm has seen the Zacks Consensus Estimate for its current year earnings increasing 6.3% over the last 60 days.Emergent BioSolutions Inc. (EBS) : This life sciences company has seen the Zacks Consensus Estimate for its current year earnings increasing 34.3% over the last 60 days.LivaNova PLC (LIVN) : This medical device company has seen the Zacks Consensus Estimate for its curr ...